CXCL10 and IFN-? Mediate Myocarditis Post-COVID19 mRNA Vaccination [mouse]
The mRNA vaccines against COVID-19 are highly effective yet associated with rare myocarditis cases, particularly in young males post-second dose. Here we explore the mediators of this adverse effect and its potential solutions, aiming to enhance the safety of future mRNA vaccines. Analysis of post-vaccination plasma highlighted a substantial increase in CXCL10 and IFN-? levels in patients. Correspondingly, human iPSC-derived macrophages exposed to COVID-19 mRNA vaccines exhibited increased production of these two cytokines. iPSC-derived cardiomyocytes subjected to these cytokines exhibited impaired contractility, arrhythmogenicity, and myocarditis-like gene expression patterns. Genistein, an anti-inflammatory phytoestrogen, notably mitigated these effects, reducing cytokine-induced proteasomal degradation of cardiac proteins and preserving contractile function. In vivo, genistein significantly decreased cardiac injury markers and immune cell infiltration in a mouse model of cytokine-induced myocarditis. These findings underscore CXCL10 and IFN-? as key mediators of myocarditis post-mRNA vaccination and propose genistein as a potential therapeutic to mitigate associated cardiovascular risks. Overall design: For mouse samples: BALB/C mouse were divided into three groups: Control, Cytokine treatment, Cytokine + Genistein. 6 mice in each group. Mice were pretreated for 7 days with Genistein with the Cytokine+Genistein group. Then, cytokines cocktail (2.5 ug of CXCL10 and 2.5 ug IFNr) were injected into mice through tail vein. Mice heart samples were collected 4 hours after cyokines treatment and sent for bulk RNA-seq. Mice treated with vehicle (PBS) were used as control.